Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p268 | Muscle, physical activity and bone | ECTS2016

Association of frailty with vitamin D in elderly women

Alekna Vidmantas , Mastaviciute Asta , Kilaite Justina , Tamulaitiene Marija

Objective: To investigate the relationship of frailty with vitamin D in community dwelling elderly women.Materials and methods: A retrospective cross-sectional study was performed on women over 60 years who were not using vitamin D supplementations. Frailty status was defined using Fried’s criteria: weakness, low walking speed, low physical activity, weight loss, exhaustion. Participants were classified as robust, prefrail and frail if they scored 0...

ba0001pp31 | Bone biomechanics and quality | ECTS2013

A GWAS in an extreme high bone mass population shows excess signal from genes associated with BMD in the normal population

Gregson Celia L , Leo Leo Paul J , Clark Graeme R , Smith George Davey , Brown Matthew A , Tobias Jon H , Duncan Duncan Emma L

Extreme high bone mass (HBM) may be monogenic (e.g. due to mutations in SOST or LRP5) or polygenic, due to variants in the same genes determining bone mineral density (BMD) as found in the general population. We aimed to determine the genetic cause underlying HBM in an extreme HBM population.258 unexplained HBM cases (defined as L1 Z-score ≥+3.2 plus total hip Z-score ≥+1.2, or total hip Z-score ≥+3.2 and L1 <...

ba0001pp435 | Osteoporosis: treatment | ECTS2013

Denosumab's dynamic CTX profile is maintained over 6 years of treatment: first 3 years of the FREEDOM extension study

Roux C , McClung MR , Franchimont N , Adami S , Ebeling PR , Reid IR , Resch H , Weryha G , Daizadeh N , Wang A , Wagman RB , Eastell R

Denosumab (DMAb) has a unique profile of bone resorption inhibition: CTX decreases rapidly by 3 days and inhibition is released at the end of the 6-month dosing interval, when DMAb serum levels decrease (McClung NEJM 2006). The dynamic CTX inhibition profile is not curtailed by continued treatment. In the 3-year FREEDOM study, CTX values at 6 months were influenced by baseline CTX values and days since the 1st injection (Eastell JBMR 2011). With 3 additional ...

ba0002oc21 | Miscellaneous | ICCBH2013

A randomized, double-blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone

Boyce Alison M , Kelly Marilyn H , Brillante Beth A , Kushner Harvey , Wientroub Shlomo , Riminucci Mara , Bianco Paolo , Robey Pamela G , Collins Michael T

Fibrous dysplasia (FD) is a benign skeletal disease caused by activating mutations of Gsα. These mutations lead to formation of abnormal and mechanically unsound bone and fibrotic tissue. Clinical sequelae include deformity, fracture, and pain. Studies in bisphosphonates have shown improvement in bone pain and inconsistent effects on FD mineralization; however interpretation has been limited by a lack of controlled trials.Objecti...

ba0002p111 | (1) | ICCBH2013

Vitamin D status and association to bone health in 781 healthy 8–11 years old Danish school children: preliminary results from the Opus school meal study

Petersen R A , Damsgaard C T , Dalskov S , Sorensen L B , Laursen R P , Hjorth M F , Andersen R , Tetens I , Krarup H , Astrup A , Michaelsen K F , Molgaard C

Background: Low vitamin D concentrations among children and adolescents at northern latitudes are frequently observed. Also, inverse associations between 25-hydroxyvitamin D (25(OH)D) and PTH concentrations have been found in children of different ages. More studies on the link between vitamin D status and childhood bone health are needed.Objective: To evaluate the status of serum 25(OH)D in autumn and the association between 25(OH)D concentrations and b...

ba0002p114 | (1) | ICCBH2013

Association between parameters of bone mass measured by dual energy X-ray absorptiometry and quantitative ultrasound of proximal phalanges in children and adolescents with congenital adrenal hyperplasia

Goncalves Ezequiel M , Barbeta Vinicius J O , Bertapelli Fabio , Krahenbuhl Tathyane , Luiz Carlos B Ramalho , Martin Juan Eduardo Samur-San , Lemos-Marini Sofia H V , Guerra-Junior Gil

The chronic use of glucocorticoids in patients with congenital adrenal hyperplasia (CAH) may result in decreased bone mass. Therefore, using simple and accurate methods for assessing bone status in these patients could facilitate the treatment of disease. The purpose of this study was to verify the association between parameters of bone mass measured by dual energy X-ray absorptiometry (DXA) and quantitative ultrasound (QUS) of proximal phalanges in children adolescents with c...

ba0003pp187 | Genetics | ECTS2014

A novel mutation in IFITM5, encoding BRIL, impairs osteoblast production of PEDF and causes atypical type VI osteogenesis imperfecta

Reich Adi , Farber Charles R , Barnes Aileen M , Becerra Patricia , Rauch Frank , Cabral Wayne A , Bae Alison , Glorieux Francis H , Clemens Thomas L , Marini Joan C

Osteogenesis imperfecta (OI) type V is caused by a unique dominant mutation (c.−14C>T) in IFITM5, which encodes BRIL, a transmembrane ifitm-like protein most strongly expressed in osteoblasts, while type VI OI is caused by recessive null mutations in SERPINF1, encoding pigment epithelium-derived factor (PEDF). We identified a 25-year-old woman with severe OI, whose dermal fibroblasts and cultured osteoblasts displayed minimal secretion of PEDF, but ...

ba0004oc10 | (1) | ICCBH2015

Lack of PEDF within the bone matrix is associated with osteoidosis and abnormally high bone mineral content

Fratzl-Zelman Nadja , Schmidt Ingo , Roschger Paul , Roschger Andreas , Reich Adi , Glorieux Francis H. , Wagermaier Wolfgang , Fratzl Peter , Klaushofer Klaus , Marini Joan C. , Rauch Frank

Background and methods: Pigment epithelium-derived factor (PEDF) is a potent antiangiogenic factor, ubiquitously expressed and secreted in human tissues. Hypertrophic cartilage and osteoblasts express PEDF that binds to type I collagen and glycosaminoglycans in the extracellular matrix. Two rare forms of osteogenesis imperfecta (OI) with intact collagen synthesis are associated with PEDF deficiency. Histological observations revealed excessive osteoid formation and prolonged m...

ba0004p97 | (1) | ICCBH2015

Dysosteosclerosis from a unique mutation in SLC29A3

Turan Serap , Mumm Steven , Gottesman Gary S , Abali Saygin , Serpil Bas , Atay Zeynep , William H McAlister , Whyte Michael P , *Dr. Turan and Dr. Mumm contributed equally to this work

Dysosteosclerosis (DSS) is the rare osteopetrosis (OPT) distinguished by metaphyseal osteosclerosis with relative radiolucency of widened diaphyses and platyspondyly. In 2012, mutations in the SLC29A3 gene were discovered to cause DSS.Here, we report a new case of DSS presenting with severe anemia and having a unique homozygous mutation in SLC29A3.Our patient was the 3rd child of consanguineous Turkish parents. She present...